Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 12/20 | 0.65 |
| ▸ | MEF2D | Q14814 | 12/20 | 0.65 |
| ▸ | EP300 | Q09472 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354210 | 1.00 | HDAC4 (0.65) | HDAC4MEF2DEP300KDM4EMAPK1 | |
| SCHEMBL21232170 | 0.93 | HDAC4 (0.61) | HDAC4MEF2DEP300KDM4EMAPK1 | |
| SCHEMBL21221152 | 0.88 | HDAC4 (0.70) | HDAC4MEF2DEP300SMN1; SMN2RAB9A | |
| SCHEMBL21221150 | 0.88 | HDAC4 (0.70) | HDAC4MEF2DEP300SMN1; SMN2RAB9A | |
| SCHEMBL21232199 | 0.85 | HDAC4 (0.73) | HDAC4MEF2DEP300 | |
| SCHEMBL21232190 | 0.79 | HDAC4 (0.66) | HDAC4MEF2DEP300 | |
| SCHEMBL29355747 | 0.79 | HDAC4 (0.66) | HDAC4MEF2DEP300 | |
| SCHEMBL21221207 | 0.79 | HDAC4 (1.00) | HDAC4MEF2DEP300 | |
| SCHEMBL21232207 | 0.79 | HDAC4 (0.51) | HDAC4MEF2DEP300BACE1 | |
| SCHEMBL29351797 | 0.79 | HDAC4 (0.51) | HDAC4MEF2DEP300BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | STANDARD LLC (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190241504-A1 | Novel Myocyte Enhancer Factor 2 (MEF2) modulators | STANDARD LLC | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | MEF2D, MYLK2, TNNT2 | HDAC4 81/4885MEF2D 1/4885EP300 35/4885 |
| US-20190241504-A1 | Novel Myocyte Enhancer Factor 2 (MEF2) modulators | MEF2D, MYLK2, MYOF | HDAC4 97/4885MEF2D 1/4885EP300 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.